Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenlin Ju

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Cancer Research|May 27, 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao, Steven Kornblau, Stephen Safe, et al.
BMC Cancer|February 25, 2014
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylationKimberly C Wiegand, Bryan T Hennessy, Samuel Leung, et al.
Gynecologic Oncology|October 19, 2019
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG studyShannon N Westin, Michael W Sill, Robert L Coleman, et al.
Cancer|March 17, 2023
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancerKatherine I Foster, Kenna R M Shaw, Jeff Jin, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingMelanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, et al.
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
Cancer Discovery|October 11, 2011
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stabilityLydia W T Cheung, Bryan T Hennessy, Jie Li, et al.
Molecular Cancer Therapeutics|February 4, 2010
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park, Rosalia Rabinovsky, Mark Carey, et al.
Scientific Reports|August 27, 2024
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft modelsChia-Chin Wu, Licai Huang, Zhongting Zhang, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Cancer Research|May 27, 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao, Steven Kornblau, Stephen Safe, et al.
BMC Cancer|February 25, 2014
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylationKimberly C Wiegand, Bryan T Hennessy, Samuel Leung, et al.
Gynecologic Oncology|October 19, 2019
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG studyShannon N Westin, Michael W Sill, Robert L Coleman, et al.
Cancer|March 17, 2023
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancerKatherine I Foster, Kenna R M Shaw, Jeff Jin, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor SignalingMelanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, et al.
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
Cancer Discovery|October 11, 2011
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stabilityLydia W T Cheung, Bryan T Hennessy, Jie Li, et al.
Molecular Cancer Therapeutics|February 4, 2010
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line setEun Sung Park, Rosalia Rabinovsky, Mark Carey, et al.
Scientific Reports|August 27, 2024
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft modelsChia-Chin Wu, Licai Huang, Zhongting Zhang, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Pageof 9